

Company name Eos SENOLYTIX, Inc. \* Website <https://eossenolytix.com> \*

CEO name Kevin Slawin, MD\* Cell phone number

Select a CATEGORY: Biotech/Pharma or Medical Devices or Health IT/Digital \*

Select up to two SESSIONS per abstract from the list below

- Aging Redefined: Breakthroughs in Science and Technology in Longevity
- **Executive Summary / Investment Rationale-** Eos SENOLYTIX is a longevity company using advanced technologies to develop novel therapeutics targeting the fundamental mechanisms of aging. By attacking aging via two pathways, both via a single age-specific target, the lower MMP that develops in the mitochondria as we age, Eos SENOLYTIX addresses the fundamental “causes” of aging, leaving all the “effects” of aging to repair themselves.
- **Core Technology-** Our peptides work via a completely novel mechanism of action, targeting the lower and declining  $\Delta\Psi_m$  found in aging and senescent cells that develops as we age and that occurs in all living organisms (1) to steadily and profoundly eliminate senescent cells throughout the body in the medium to longer term, and (2) to enhance the efficiency of mitochondrial function in aging cells in the short term, with no apparent adverse side effects observed. By targeting the fundamental processes driving aging and aging-related diseases, we have a unique opportunity to intervene in the aging process in ways that we once thought impossible.
- **Product Profile/Pipeline-** Its lead programs, focused on our proprietary gerotherapeutic peptides include:
  - **PTC-2105** for Obesity/Glucose Metabolic Disorders with and without GLP-1 agonists and for Sarcopenia and Sarcopenic Obesity.
  - **PTC-2107** for Cognitive and Neurodegenerative Disorders.
- **Business Strategy- PTC-2105**, administered at low dose in combination with semaglutide (“SMG”) “fixes the defect” of lean body mass loss seen with SMG and all GLP-1 agonists, and yields an astonishing 100 – 150% increase in exercise capacity. **PTC-2105** at higher doses as monotherapy improves body composition, reducing % fat mass, but increasing % lean body and bone mass in a dose dependent fashion. Thus, we plan to initially develop **PTC-2105** in combination with GLP-1 agonist to “piggyback” on their current market dominance and then to move those patients to monotherapy at higher doses after a period on combination therapy.
- **What's Next?** - Eos SENOLYTIX is raising a Series A financing and plans to file an IND for its lead clinical candidate, **PTC-2105**, within the next 12 months.